



PRESS RELEASE  
23 MARCH 2015  
5 :45 PM CET

## Cardio3 BioSciences Announces Details of Upcoming Full-year 2014 Financial Results

*Conference call scheduled for Thursday, March 26 at 2:00 p.m. CET / 9:00 a.m. EDT*

**Mont-Saint-Guibert, Belgium** - Cardio3 BioSciences (C3BS) (Euronext Brussels and Paris: CARD), a leader in the discovery and development of specialized cell therapies, today announced that it will report its financial results for the year ended December 31, 2014, on Thursday, March 26, 2015.

A conference call will be held on Thursday, March 26, 2015 at 2:00 p.m. CET / 9:00 a.m. EDT to review the financial results. Christian Homsy, Chief Executive Officer, and Patrick Jeanmart, Chief Financial Officer will deliver a brief presentation, **which will be available to download from [here](#) 15 minutes before the call commences**, followed by a Q&A session. Participants are asked to call the assigned number approximately five minutes before the conference call begins.

The call can be accessed by dialing the numbers below and **quoting conference ID 10703467**.

• Participant International Dial-In	+ 44 (0)1452 541003
• Belgium	011500193
• France	0170700780
• United States	1-646-741-2120

A recording of the presentation will be available on the Cardio3 Biosciences website following the call.

\*\*\* END \*\*\*

For more information, please contact:

**Cardio3 BioSciences**

Christian Homsy, CEO

Julie Grade, Corporate Communications Manager

**For Europe: Consilium Strategic Communications**

Amber Bielecka, Chris Welsh, Laura Thornton

**For France : NewCap**

Pierre Laurent, Nicolas Mérieau

**For the U.S: The Ruth Group**

[www.c3bs.com](http://www.c3bs.com)

Tel: +32 10 39 41 00

[jgrade@c3bs.com](mailto:jgrade@c3bs.com)

Tel : +44 20 3709 5700

[cardio3@consilium-comms.com](mailto:cardio3@consilium-comms.com)

Tél. : + 33(0)1 44 71 94 94

[cardio3@newcap.fr](mailto:cardio3@newcap.fr)

Tel: +1 646 536 7012 / 7014



PRESS RELEASE

23 MARCH 2015

5 :45 PM CET

Lee Roth (Investors), Kirsten Thomas (Media)

[lroth@theruthgroup.com](mailto:lroth@theruthgroup.com)

[kthomas@theruthgroup.com](mailto:kthomas@theruthgroup.com)

To subscribe to Cardio3 BioSciences' newsletter, visit [www.c3bs.com](http://www.c3bs.com).

 Follow us on Twitter [@Cardio3Bio](https://twitter.com/Cardio3Bio).

## About Cardio3 BioSciences

Cardio3 BioSciences is a leading clinical-stage biotechnology company focused on the discovery and development of cell-therapy treatments with clinical programs initially targeting indications in cardiovascular disease and oncology. Founded in 2007 and based in the Walloon region of Belgium, Cardio3 BioSciences leverages research collaborations in the USA with the Mayo Clinic (MN, USA) and Dartmouth College (NH, USA). The Company's lead product candidate in cardiology is C-Cure<sup>®</sup>, an autologous stem cell therapy for the treatment of congestive heart failure. The Company's lead product candidate in oncology is CAR-NKG2D, an autologous CAR T-cell product candidate using NKG2D, a Natural Killer (NK) cell receptor designed to target ligands present on most tumor types, including blood cancers and solid tumors. Cardio3 BioSciences is also developing medical devices for enhancing the delivery of bio therapeutic agents into the heart (C-Cath<sub>ez</sub><sup>®</sup>) and for the treatment of mitral valve defects.

Cardio3 BioSciences' shares are listed on Euronext Brussels and Euronext Paris under the ticker symbol CARD.

To learn more about Cardio3 BioSciences, please visit [www.c3bs.com](http://www.c3bs.com)

## Forward looking statements

*C3BS-CQR-1, C-Cure, CAR-NKG2D, C-Cath<sub>ez</sub>, OnCyte, Cardio3 BioSciences and the Cardio3 BioSciences, C-Cath<sub>ez</sub>, CHART-1, CHART-2 and OnCyte logos are trademarks or registered trademarks of Cardio3 BioSciences SA, in Belgium, other countries, or both. Mayo Clinic holds equity in Cardio3 BioSciences as a result of intellectual property licensed to the company. In addition to historical facts or statements of current condition, this press release contains forward-looking statements, which reflect our current expectations and projections about future events, and involve certain known and unknown risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. These forward-looking statements are further qualified by important factors, which could cause actual results to differ materially from those in the forward-looking statements, including timely submission and approval of anticipated regulatory filings; the successful initiation and completion of clinical trials, including Phase III clinical trials for C-Cure<sup>®</sup> and Phase I/IIa clinical trial for CAR-NKG2D additional clinical results validating the use of adult autologous stem cells to treat heart failure and CAR T-cell autologous therapy to treat cancer; satisfaction of regulatory and other requirements; actions of regulatory bodies and other governmental authorities; obtaining, maintaining and protecting intellectual property, our ability to enforce our patents against infringers and defend our patent portfolio against challenges from third parties, competition from others developing products for similar uses, our ability to manage operating expenses, and our ability to obtain additional funding to support our business activities and establish and maintain strategic business alliances and new business initiatives. In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. We explicitly disclaim any obligation to update any forward-looking statements.*